Skip to content
StackItSmart
BHuman cohort / observational

Exemestane

Aromasin

Exemestane (Aromasin) is an oral, irreversible ("suicide-substrate") steroidal aromatase inhibitor originally developed to suppress estrogen production in postmenopausal breast cancer. In men it is used off-label as an ancillary to lower estradiol by blocking the conversion of androgens to estrogens. The main risks are the direct consequences of driving estrogen too low: accelerated bone mineral density loss (osteopenia/fracture risk), an unfavorable shift in cholesterol (falling HDL, rising LDL:HDL ratio), joint pain/stiffness (arthralgia), and estrogen-dependent effects on mood, libido and cardiovascular health. Direct human data in men is extremely limited (a single small 12-subject dose-finding study); most safety evidence is extrapolated from postmenopausal women, where robust RCT data exist. This is a prescription drug that meaningfully alters hormonal physiology and should only be used under medical supervision with bloodwork; it is not benign and should never be used to "crush" estrogen.

Clinical readoutAncillary · aromatase-inhibitor
Hepatic strainLow
CardiovascularModerate
HPTA suppressionLow
Half-life
8.9 h
Route
Oral
Evidence
B
Active
Estrogen suppression pe…
8.9 h17.8 h26.7 h35.6 h44.5 h
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Terminal half-life approximately 8.9 hours measured in young men after a 25 mg oral dose; product labeling in women cites ~24 h. Because inhibition is irreversible, biological (estrogen-suppressing) effect outlasts plasma clearance.
Pharmacology

Mechanism of action

Exemestane is a steroidal (type I) aromatase inhibitor. As an androstenedione analogue it binds the aromatase (CYP19A1) enzyme and is processed as a false substrate, forming a covalent, irreversible bond that permanently inactivates the enzyme ("suicide inhibition"). Because aromatase converts androgens (testosterone, androstenedione) to estrogens (estradiol, estrone), this blockade lowers circulating estradiol. In men, reduced estradiol relieves negative feedback on the hypothalamic-pituitary axis, raising LH/FSH and consequently testosterone; a single small human study in young eugonadal males confirmed a roughly 38% fall in estradiol with a reciprocal ~60% rise in testosterone. Because inactivation is irreversible, recovery of estrogen synthesis requires synthesis of new enzyme.
Kinetics

Pharmacokinetics

Half-life

Terminal half-life approximately 8.9 hours measured in young men after a 25 mg oral dose; product labeling in women cites ~24 h. Because inhibition is irreversible, biological (estrogen-suppressing) effect outlasts plasma clearance.

Active duration

Estrogen suppression persists well beyond a single plasma half-life owing to irreversible enzyme inactivation; in single-dose studies estrogen suppression lasted several days and returned toward baseline roughly 1-2 weeks after stopping. Steady state is reached in about 5 days with once-daily dosing.

Route

Oral. Absorption is rapid (peak concentration ~1-2.6 h). A high-fat meal increases absorption (Cmax/AUC), so labeling recommends taking after food; this is a monitoring/consistency consideration, not a performance one.

Metabolism & clearance

Extensively hepatically metabolized, principally via CYP3A4 and aldoketoreductases (oxidation of the 17-position and reduction of the double bond); metabolites are largely inactive. Eliminated in roughly equal amounts in urine and feces; negligible unchanged drug in urine. Exposure is increased by hepatic or renal impairment. Linear pharmacokinetics with no meaningful accumulation on repeat dosing.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Lowers circulating estradiol/estrone by irreversibly inactivating aromatase (in men, ~38% estradiol reduction at 25 mg/day in a small study)
  • In men, reciprocal rise in testosterone (~60% in the same study) and increases in LH/FSH via reduced estrogen negative feedback
  • In postmenopausal women, used to reduce estrogen-driven breast cancer recurrence (established oncologic indication)
  • Mild androgenic character of the parent steroid and its 17-hydroxy metabolite (unlike non-steroidal AIs), of uncertain clinical relevance
  • No meaningful change in IGF-1 or plasma lipids was seen over 10 days in the small young-male study, but longer exposure in women shows adverse lipid and bone effects
Safety

Adverse effects by system

Cardiovascular

Estrogen is cardioprotective; lowering it can worsen the lipid profile. In a randomized study of healthy postmenopausal women, exemestane (unlike anastrozole/letrozole) significantly raised the LDL:HDL cholesterol ratio by 12 weeks, mainly by lowering HDL. Long-term aromatase-inhibitor class data show measurable lipid and cardiovascular-risk signals. No dedicated cardiovascular outcome data exist in men.

Hepatic

Uncommon, usually mild, transient transaminase (AST/ALT) and alkaline phosphatase/GGT elevations reported in phase I dosing studies. No human case met Hy's law criteria in the retrieved trials. Preclinical (zebrafish) data show dose-dependent liver toxicity via p53-mediated apoptosis, but human clinically significant hepatotoxicity is rare.

Endocrine / HPTA

The core pharmacologic effect: suppression of estradiol with compensatory rise in LH/FSH and testosterone in men. Over-suppression of estradiol causes an estrogen-deficient state (see bone, joint, lipid, mood, libido effects). Hot flushes are common.

Reproductive

By lowering estradiol and raising testosterone, exemestane alters the sex-steroid milieu. Very low estradiol in men can impair libido, erectile function and possibly spermatogenesis, since estradiol has essential roles in male sexual function and bone/fertility. Human reproductive-outcome data for this off-label use are inadequate.

Neuropsychiatric

Estrogen influences mood; low estradiol states are associated with depressed mood, irritability, fatigue and insomnia. Fatigue, headache, dizziness and sleepiness were reported in phase I studies. Dedicated psychiatric outcome data in men are lacking; treat as biologically plausible and monitor.

Renal

No specific nephrotoxicity identified in the retrieved human literature. Renal impairment increases drug exposure (~3-fold in labeling), so clearance—not direct kidney injury—is the concern. No adequate data specific to this population.

Hematologic

No consistent clinically significant hematologic toxicity in the retrieved human data; isolated minor blood-count changes (e.g., basophils) noted in a phase I study. Estrogen suppression is not a recognized cause of major hematologic harm here. No adequate data specific to men using it as an ancillary.

Dermatologic

Sweating/hot flushes are common; increased sweating and, less commonly, rash or hair thinning are reported in the class. No serious dermatologic toxicity established.

Recovery

HPTA suppression & recovery

Suppression: Not classically HPTA-suppressive in the SERM sense; in men it tends to raise gonadotropins and testosterone by removing estrogen negative feedback. The real endocrine hazard is the opposite problem—driving estradiol too low, producing an estrogen-deficient state (bone, joint, lipid, mood, libido harm).

Because aromatase inhibition is irreversible at the enzyme level, estrogen synthesis recovers only as new enzyme is produced; single-dose human data show estradiol returning toward baseline within roughly 1-2 weeks after stopping. Individual recovery of the hormonal axis varies and can be confounded by concurrent anabolic-steroid use. This is not a substitute for a structured recovery plan: anyone using exemestane to manage estrogen during or after androgen use should have hormones (estradiol, total/free testosterone, LH, FSH) assessed and managed by an endocrinologist rather than self-titrating.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Estradiol (sensitive/LC-MS assay preferred in men) to avoid over-suppressionTotal and free testosterone; LH and FSHFasting lipid panel (HDL, LDL, LDL:HDL ratio, triglycerides)Liver function tests (AST, ALT, ALP, GGT, bilirubin)Bone mineral density (DXA) with longer-term use; consider vitamin D and calcium statusRenal function if impairment suspected

Cadence: Baseline before use; recheck hormones and lipids within ~4-8 weeks of starting or dose change; liver enzymes periodically; DXA at baseline and roughly every 1-2 years with prolonged use—all directed by a clinician.

Warning signs — seek care
  • Bone or joint pain, new fractures, height loss (bone loss)
  • Persistent arthralgia/stiffness limiting function
  • Symptoms of very low estrogen: crashing libido, erectile dysfunction, low mood/depression, fatigue, joint aching, dry skin
  • Chest pain, palpitations, or other cardiovascular symptoms
  • Jaundice, dark urine, right-upper-quadrant pain, or nausea (possible liver injury)
  • Severe or persistent hot flushes, insomnia, or mood disturbance
Do not use if

Contraindications

  • Premenopausal women / women of childbearing potential and pregnancy or breastfeeding (estrogen suppression; potential fetal harm)
  • Known hypersensitivity to exemestane or excipients
  • Caution/avoid with pre-existing osteoporosis or high fracture risk without bone protection and specialist oversight
  • Caution with dyslipidemia or established cardiovascular disease given adverse lipid shift
  • Hepatic or renal impairment (increased drug exposure) — requires clinician oversight
  • Concurrent strong CYP3A4 inducers (e.g., rifampicin) can substantially lower exemestane levels; interacting drugs warrant medical review
  • Not appropriate for self-directed use to maximally suppress estrogen
Combinations

Interaction profile

  • ModerateWith another aromatase inhibitor: Hormonal
  • ModerateWith a SERM: Hormonal
  • ModerateWith an anabolic steroid: Hormonal
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Direct human evidence in men using exemestane as an ancillary is minimal (one small 12-subject study); most risk data are extrapolated from postmenopausal women—treat any dosing as uncertain and clinician-guided.
  • Do not aim to 'crush' or minimize estradiol: estrogen is essential in men for bone, joints, lipids, mood, libido and cardiovascular health. Over-suppression causes real harm.
  • Get baseline and follow-up bloodwork (estradiol by a sensitive assay, testosterone, LH/FSH, lipids, liver enzymes) rather than dosing by feel.
  • With prolonged use, protect bone: DXA monitoring, adequate vitamin D and calcium, and clinician input on bone-protective measures.
  • Stop and seek medical care for jaundice/dark urine/RUQ pain (possible liver injury), chest pain or palpitations, new fractures or significant bone/joint pain, or severe mood disturbance.
  • Any estrogen or hormonal-axis management during or after androgen use should be overseen by an endocrinologist, not self-managed.
  • This monograph does not endorse use; it is prescription-only and should be used under medical supervision.
Evidence

Citations (9)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Exemestane is a potent irreversible steroidal aromatase inhibitor; in young eugonadal men 25 mg/day suppressed estradiol ~38% with a reciprocal ~60% rise in testosterone, terminal half-life ~8.9 h, rapid absorption, lipids and IGF-1 unchanged over 10 days, well tolerated.

    RCTPharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males.PMID 14671195 ↗

  2. 02

    Exemestane has linear pharmacokinetics, reaches steady state by ~day 5 with no accumulation, is absorbed rapidly (Cmax ~0.9-2.6 h), and produced only occasional mild transaminase elevations in a phase I multiple-dose study.

    RCTPMID 12146000 ↗

  3. 03

    Single-dose exemestane suppresses serum/urinary estrogen for several days returning toward baseline by ~2 weeks; food increases absorption; adverse events were mild (hot flushes, sleepiness) with an isolated rise in GPT/ALP/GGT in one 50 mg subject.

    RCTPMID 12145999 ↗

  4. 04

    In a randomized study of healthy postmenopausal women, exemestane (unlike anastrozole/letrozole) significantly increased the LDL:HDL cholesterol ratio by 12 weeks, largely by lowering HDL, and all three AIs increased bone-resorption markers.

    RCTPMID 18029171 ↗

  5. 05

    In a placebo-controlled 2-year study, exemestane caused greater femoral-neck BMD loss than placebo (2.72% vs 1.48%/yr, p=0.024) and a moderate HDL decrease, both partially reversible after stopping.

    RCTPMID 16963261 ↗

  6. 06

    Aromatase-inhibitor class therapy is associated with bone density loss and potential adverse effects on lipids and cardiovascular risk, while being better tolerated than tamoxifen for thromboembolic events.

    ReviewAdjuvant aromatase inhibitor therapy: outcomes and safety.PMID 20133065 ↗

  7. 07

    Aromatase-inhibitor-associated musculoskeletal symptoms (arthralgia/stiffness) are common adverse events that often lead to drug discontinuation.

    RCTPMID 29752687 ↗

  8. 08

    Exemestane in combination with bosutinib produced hepatotoxicity in 26% of patients but no case met Hy's law criteria, supporting a low rate of clinically significant exemestane liver injury.

    RCTPMID 24674873 ↗

  9. 09

    Exemestane induces dose-dependent hepatotoxicity in zebrafish larvae via p53-mediated apoptosis and oxidative stress (preclinical signal only).

    PreclinicalPMID 41114735 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice